In addition, combining AKT inhibitors with inhibitors of androgen signaling increases anti-tumor effects in phosphatase and tensin homolog (PTEN) null tumor cell lines and tumor models of prostate cancer.30 This evidence concerns the gene AKT1 and prostate carcinoma.